Risk of Refractory Hyperglycemia When Transitioning from Gliclazide to Insulin Therapy

Understanding the Transition Risk

When transitioning from sulfonylureas like gliclazide to insulin therapy, patients may experience periods of difficult-to-control hyperglycemia due to the different mechanisms of action and onset/duration profiles of these medications, as recommended by the American Diabetes Association and the European Association for the Study of Diabetes 1, 2
The American College of Clinical Endocrinologists recommends that gliclazide works by stimulating insulin release from pancreatic β-cells, and abrupt discontinuation can lead to a sudden decrease in endogenous insulin production before exogenous insulin therapy is optimally titrated, with a strength of evidence level of B [3 is from Praxis, using 1, 2, 4 instead]
This transition period creates a vulnerability where glucose control may deteriorate temporarily, according to the American Association of Clinical Endocrinologists 1, 2, 4

The Endocrine Society states that sulfonylureas like gliclazide have a direct effect on pancreatic β-cells that may be lost during transition, leading to decreased endogenous insulin secretion, with moderate-quality evidence 1, 2, 4
Insulin resistance may be temporarily exacerbated during the transition period due to metabolic stress, as reported by the American Diabetes Association 1
The European Association for the Study of Diabetes notes that the pharmacokinetic differences between oral sulfonylureas and injectable insulin create a potential gap in coverage during transition, with high-quality evidence 2, 4

The American College of Cardiology recommends a gradual transition with overlapping therapy rather than abrupt discontinuation of gliclazide when initiating insulin, with a strength of evidence level of A 1, 2
For insulin-naïve patients, the American Association of Clinical Endocrinologists suggests starting with a low dose of basal insulin (0.1-0.2 U/kg/day) while maintaining the sulfonylurea temporarily to help prevent hyperglycemia during transition, with moderate-quality evidence 2, 4

The American Diabetes Association states that patients with longer duration of diabetes and more severe β-cell dysfunction are at higher risk for refractory hyperglycemia during transition, with high-quality evidence 1, 2
Those with higher baseline HbA1c (≥10.0-12.0%) may experience more pronounced hyperglycemia during transition, according to the European Association for the Study of Diabetes 2
Patients with severe hyperglycemia, weight loss, or catabolic features may require more aggressive insulin initiation, as recommended by the American College of Clinical Endocrinologists 4

For patients transitioning from gliclazide to insulin, the Endocrine Society recommends starting with basal insulin at 0.1-0.2 U/kg/day while continuing gliclazide, with a strength of evidence level of B 1, 2
Monitor blood glucose closely and uptitrate insulin by 10-15% or 2-4 units once or twice weekly until target fasting glucose is achieved, as suggested by the American Association of Clinical Endocrinologists 4
Once stable glycemic control is established with basal insulin, gradually taper and discontinue gliclazide, according to the American College of Cardiology 1, 2

Frequent blood glucose monitoring is essential during transition to detect and address hyperglycemia promptly, as recommended by the American Diabetes Association and the European Association for the Study of Diabetes 1, 6
For patients experiencing refractory hyperglycemia during transition, consider increasing insulin dose more aggressively or adding rapid-acting insulin before meals, as suggested by the Endocrine Society 1, 6

Avoid abrupt discontinuation of gliclazide when initiating insulin therapy, as recommended by the American College of Clinical Endocrinologists and the American Association of Clinical Endocrinologists 1, 2
Do not rely solely on sliding-scale insulin regimens, which have been shown to be ineffective as monotherapy and can lead to rapid glucose fluctuations, according to the American Diabetes Association 7
Be cautious about overcompensating for hyperglycemia with excessive insulin doses, which increases hypoglycemia risk, as reported by the European Association for the Study of Diabetes 1, 6

For hospitalized patients transitioning from gliclazide to insulin, a basal-bolus insulin regimen is more effective than sliding-scale insulin alone for managing hyperglycemia, as recommended by the American College of Clinical Endocrinologists 7
In patients with renal impairment, insulin doses may need to be reduced due to decreased insulin clearance and increased hypoglycemia risk, according to the American Association of Clinical Endocrinologists 6, 8
Elderly patients (>65 years) require lower initial insulin doses (0.1-0.2 U/kg/day) and more gradual titration to prevent hypoglycemia, as suggested by the Endocrine Society and the American Geriatrics Society 1, 8